• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression

    6/4/25 8:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $LIVN alert in real time by email

    Final critical papers on RECOVER clinical study data accepted, supporting the Company's submission for coverage reconsideration

    Strong 24-month top-line data for RECOVER clinical study demonstrates durability of VNS Therapy

    In-depth analysis on suicidality at 12 months yields positive results

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it has initiated the process with the U.S. Centers for Medicare and Medicaid Services (CMS) to seek reconsideration of national Medicare coverage for VNS Therapy™ in unipolar patients with treatment-resistant depression (TRD). The first step in the process for making a National Coverage Determination (NCD) is the submission of a draft formal request for CMS reconsideration.

    Five critical articles featuring outcomes from in-depth data analyses on primary and select secondary endpoints in the RECOVER study have recently been published in or accepted by peer-reviewed journals, and the totality of data presented in these articles serves as the basis of the Company's request to CMS. The company believes these articles satisfy the Coverage with Evidence Development (CED) requirement of sharing peer-reviewed, publicly accessible results of pre-specified outcomes measured in the RECOVER study. In addition to the five articles, the request for coverage reconsideration includes strong 24-month clinical outcomes from the unipolar cohort of the RECOVER clinical study that demonstrate the substantial retention of benefits and the durability of VNS Therapy over time.

    "We have reached an important point in our pursuit to obtain national coverage for VNS Therapy for unipolar patients with depression that is difficult to treat," said Ahmet Tezel, Ph.D., Chief Innovation Officer of LivaNova. "Our follow-on analyses of the RECOVER unipolar data demonstrate that symptoms alone may not be the sole source upon which to gauge the clinical impact of treatment. Instead, symptoms, function, and quality of life taken together present a more complete picture of treatment effectiveness. We are eager to review this powerful data with CMS during the reconsideration process."

    Final Articles in Critical Series Analyze RECOVER Primary and Select Secondary Endpoint Data

    Two new in-depth analyses1,2 on primary and select secondary endpoints in the RECOVER trial have recently been published and a third accepted by peer-reviewed journals. Prior to these articles, two initial articles were published in Brain Stimulation3,4 in December 2024, completing the series of five critical articles in total.

    Collectively, the articles highlight the significant unmet need of this markedly ill population with TRD. The RECOVER data demonstrates that VNS Therapy improves symptoms, function, and quality of life in TRD patients over time. These are outcome measures identified as clinically relevant by CMS. Depressive symptoms, daily function, and quality of life taken together, as a novel composite metric, present a more complete picture of treatment effectiveness than symptoms alone. The fifth and final critical publication utilizes this composite metric and demonstrates favorable response to VNS Therapy in TRD patients who had previously failed multiple treatments, including interventional therapies. Researchers found that patients with previous ECT or TMS treatment had statistically significant and clinically meaningful benefits with active VNS Therapy. Notably, VNS Therapy is the only treatment that has demonstrated therapeutic effects in patients who previously failed ECT.

    24-Month VNS Therapy Data Show Durability, Increasing Response Across All Outcome Measures

    New top-line 24-month data from the RECOVER study show that, across all outcome measures, VNS Therapy patients in the active arm of RECOVER experienced a substantial durability of benefit from month 12 to month 24. Of those patients who at 12 months had achieved clinically meaningful benefit, the median durability of benefit was 81.3% across all outcome measures at the 24-month assessment. This is considerable durability for these unipolar patients who, at baseline in the RECOVER study, had failed more than 13 antidepressant treatments on average.

    Observing all VNS Therapy patients in the active treatment arm of the RECOVER trial from month 12 to month 24, researchers also found improvement in all outcome measures, with the median rate of response, or clinically meaningful benefit, increasing from 40.2% at month 12 to 51.6% at month 24.

    "There is no clinical evidence to demonstrate that there are any other therapies, including pharmacotherapies and interventional therapies such as electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS), that can claim this profound level of sustained durability and increasing benefit," said A. John Rush, M.D., Professor Emeritus at Duke-National University of Singapore Medical School who has spent 25 years researching VNS Therapy for TRD and served as Chief Consultant on the RECOVER trial. "These are critical findings that offer hope to treatment-resistant depression patients and their loved ones, who have struggled for years to find effective options. Patients not only stay better – they also continue to get better."

    Improvement in suicidality shows statistically significant separation as early as month three

    LivaNova conducted additional in-depth analyses specifically evaluating suicidality for the active treatment arm of RECOVER through the first 12 months of therapy. Using a composite suicidality measure5, results showed an estimated 43% higher odds of achieving meaningful improvement in suicidal ideation symptoms versus the control arm. Of specific interest, there was separation between the active and control arms on the composite suicidality metric as early as month three. Additionally, the observed separation was consistent throughout the initial 12 months.

    "The composite suicidality outcome is especially encouraging because we can see a separation between the active and control arms so early in the study," said Charles Conway, M.D., director of the Washington University Resistant Mood Disorders Center at Washington University School of Medicine in St. Louis. Conway is the RECOVER study's lead investigator. "We're eager to further evaluate the suicidality data beyond 12 months and, in the context of the overall durability story of VNS Therapy, determine whether this benefit also continues to improve over time."

    While not included in the initial submission to CMS, the suicidality data will be provided in detail to the agency upon publication in a peer-reviewed journal.

    RECOVER launched in 2019 as part of a CED framework per the CMS NCD process. For the unipolar cohort of RECOVER, enrollment was completed in March 2023, and the 12-month follow-up for those patients was completed in March 2024. No new safety issues were identified in the study.

    About RECOVER

    LivaNova's VNS Therapy™ System has been approved for the treatment of depression since earning CE Mark in 2001 and premarket approval (PMA) from the U.S. Food and Drug Administration in 2005. RECOVER stands for A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression.

    The largest randomized clinical study of its kind, RECOVER is examining up to 1,000 patients ages 18 or older who have unipolar or bipolar depression that is difficult to treat. A total of 493 adults with at least four documented unsuccessful attempts with antidepressant treatments participated in the unipolar cohort of the RECOVER study. The double-blind, randomized controlled study is assessing how VNS Therapy can offer patients relief from their depressive symptoms and improve quality of life. It is being carried out at up to 100 leading hospitals and medical centers across the United States.

    About VNS Therapy for Depression

    The VNS Therapy™ System, Symmetry™, is U.S. Food and Drug Administration-approved and indicated in the U.S. for the adjunctive long-term treatment of chronic or recurrent depression for patients 18 years of age or older who are experiencing a major depressive episode and have not had an adequate response to four or more adequate antidepressant treatments. The most commonly reported side effects are voice alteration or hoarseness, prickling or tingling in the skin, increased coughing, shortness of breath, and sore throat. Infection is the most common complication of the surgical procedure. Important safety information is available at www.livanova.com/depression/en-us/safety-information.

    References

    1. Conway CR, et al. An examination of symptoms, function, and quality of life as conjoint clinical outcome domains for treatment-resistant depression. Journal of Mood & Anxiety Disorders. April 14, 2025. DOI: 10.1016/j.xjmad.2025.100121.
    2. Sackeim HA, et al. Characterizing the effects of vagus nerve stimulation on symptom improvement in markedly treatment-resistant major depressive disorder: A RECOVER trial report. July 1, 2025. DOI: 10.1016/j.jad.2025.03.124
    3. Conway CR, et al. Vagus nerve stimulation in treatment-resistant depression: A one-year, randomized, sham-controlled trial. Brain Stimulation. Dec. 18, 2024. DOI: 10.1016/j.brs.2024.12.1191.
    4. Rush AJ, et al. Effects of vagus nerve stimulation on daily function and quality of life in markedly treatment-resistant major depression: Findings from a one-year, randomized, sham-controlled trial. Brain Stimulation. Dec. 18, 2024. DOI: 10.1016/j.brs.2024.12.1187.
    5. The composite suicidality metric was created by adding a suicidality-specific question from each of MADRS, Quick Inventory of Depressive Symptomology–Self Report, or QIDS-SR, and Quick Inventory of Depressive Symptomology–Clinical, or QIDS-C.

    About LivaNova

    LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through medical technologies, delivering life-changing solutions in select neurological and cardiac conditions. Headquartered in London, LivaNova employs approximately 2,900 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals, and healthcare systems worldwide. For more information, please visit www.livanova.com.

    Safe Harbor Statement

    This news release contains "forward-looking statements" concerning the Company's goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions, and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding the RECOVER study, the VNS Therapy™ System, Symmetry™, and the likelihood that the Company is successful in obtaining national Medicare coverage for its VNS Therapy™ System. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company's most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250604572918/en/

    LivaNova Investor Relations and Media Contacts

    +1 281-895-2382

    Briana Gotlin

    VP, Investor Relations

    [email protected]

    Deanna Wilke

    VP, Corporate Communications

    [email protected]

    Get the next $LIVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LIVN

    DatePrice TargetRatingAnalyst
    5/20/2025$60.00Peer Perform → Outperform
    Wolfe Research
    2/26/2025Outperform → Peer Perform
    Wolfe Research
    10/4/2024$65.00Buy
    Goldman
    9/17/2024$55.00 → $66.00Neutral → Outperform
    Robert W. Baird
    3/20/2024Buy
    Needham
    2/20/2024$60.00 → $70.00Neutral → Buy
    Mizuho
    9/6/2023$52.00Hold
    HSBC Securities
    7/19/2023$56.00Neutral
    Robert W. Baird
    More analyst ratings

    $LIVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

      Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced completion of the CORE-VNS study, evaluating comprehensive outcomes of real-world evidence for more than 800 people with epilepsy treated with VNS Therapy™ worldwide. With the clinical study report (CSR) now complete, the final 36-month data further validate the effectiveness of VNS Therapy for severe focal seizures in both children and adults with drug-resistant epilepsy (DRE) and demonstrate early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures. "It is c

      6/5/25 8:15:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy

      This is the latest prospective evaluation of VNS Therapy in generalized tonic-clonic seizures Findings include 77% median seizure reduction and 43% of participants reporting seizure freedom at 24-month visits LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that 24-month data on generalized tonic-clonic (GTC) seizures in people with drug-resistant epilepsy (DRE) from the CORE-VNS three-year study have been published in Epilepsia1. Several CORE-VNS study findings were highlighted in the recent article on GTC seizures in DRE patients who received VNS Therapy™, including: At 12 months, the median reduction in GTC seizure frequency was 74%, and t

      6/5/25 8:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression

      Final critical papers on RECOVER clinical study data accepted, supporting the Company's submission for coverage reconsideration Strong 24-month top-line data for RECOVER clinical study demonstrates durability of VNS Therapy In-depth analysis on suicidality at 12 months yields positive results LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it has initiated the process with the U.S. Centers for Medicare and Medicaid Services (CMS) to seek reconsideration of national Medicare coverage for VNS Therapy™ in unipolar patients with treatment-resistant depression (TRD). The first step in the process for making a National Coverage Determination (NCD)

      6/4/25 8:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LIVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $LIVN
    Financials

    Live finance-specific insights

    See more

    $LIVN
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form 4 filed by Chief Innovation Officer Tezel Ahmet

      4 - LivaNova PLC (0001639691) (Issuer)

      4/1/25 9:01:37 PM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • President, Global Epilepsy Bolton Stephanie converted options into 6,024 units of Ordinary Shares and covered exercise/tax liability with 2,835 units of Ordinary Shares, increasing direct ownership by 33% to 12,751 units (SEC Form 4)

      4 - LivaNova PLC (0001639691) (Issuer)

      4/1/25 9:01:28 PM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Makatsaria Vladimir converted options into 9,330 units of Ordinary Shares and covered exercise/tax liability with 5,046 units of Ordinary Shares (SEC Form 4)

      4 - LivaNova PLC (0001639691) (Issuer)

      4/1/25 9:01:18 PM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

      Delivered high-single-digit revenue growth, double-digit organic revenue growth, and continued operating margin expansion Raised full-year 2025 revenue guidance; updated full-year 2025 guidance now incorporates impact of SNIA decision and currently applicable tariffs Completed premarket approval submission for the aura6000™ System intended to treat obstructive sleep apnea Announced 12-month, top-line OSPREY data demonstrating strong response and sustained therapeutic impact for patients who received proximal hypoglossal nerve stimulation for obstructive sleep apnea LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the first quarter

      5/7/25 6:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova to Announce First-Quarter 2025 Results

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2025 results on Wednesday, May 7, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its first-quarter 2025 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 047836. A replay will be available on the LivaN

      3/26/25 8:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2024 results and issued full-year 2025 guidance. Financial Summary and Highlights(1) Fourth-quarter revenue of $321.8 million increased 3.8% on a reported basis, 4.7% on a constant-currency basis, and 6.8% on an organic basis as compared to the prior-year period Fourth-quarter U.S. GAAP diluted earnings per share of $1.02 and adjusted diluted earnings per share of $0.81 Full-year 2024 revenue of $1.25 billion increased 8.7% on a reported basis, 9.3% on a constant-currency basis, and 10.7% on an organic basis as compared to the prior-year Full-year 2024 U.S. GAAP

      2/25/25 6:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice

      1/6/25 9:00:00 AM ET
      $ABT
      $BMY
      $IRM
      $LIVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Real Estate Investment Trusts
      Real Estate
    • LivaNova Appoints Susan Podlogar as a New Director

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced its Board of Directors has appointed Susan Podlogar to the Board, effective today. Podlogar will serve on the Compensation and Human Capital Management Committee for the Board. "LivaNova's Board of Directors is pleased to welcome Susan Podlogar," said William Kozy, Chair of the Board. "Susan is a visionary leader with three decades of experience in leading business, talent, and cultural transformations at recognized global companies. She possesses a sharp understanding of the ever-changing global business landscape and will be a tremendous asset to the Board." Podlogar's career spans 30 years, holding key g

      10/8/24 9:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer (CINO), effective May 13, 2024. In this newly created position, Tezel will leverage his career of more than 20 years in research and development (R&D) to establish an integrated innovation function at LivaNova that will accelerate the Company's development of new technologies. In this capacity, Tezel will join the LivaNova Executive Leadership Team. "I am very pleased to welcome Ahmet to the LivaNova team. At LivaNova, our commitment to pioneering innovation remains unwavering, and Ahmet's arrival marks a significant step in advanci

      4/30/24 9:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LIVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • LivaNova upgraded by Wolfe Research with a new price target

      Wolfe Research upgraded LivaNova from Peer Perform to Outperform and set a new price target of $60.00

      5/20/25 8:01:26 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova downgraded by Wolfe Research

      Wolfe Research downgraded LivaNova from Outperform to Peer Perform

      2/26/25 7:12:54 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Goldman initiated coverage on LivaNova with a new price target

      Goldman initiated coverage of LivaNova with a rating of Buy and set a new price target of $65.00

      10/4/24 7:42:40 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LIVN
    SEC Filings

    See more
    • SEC Form SD filed by LivaNova PLC

      SD - LivaNova PLC (0001639691) (Filer)

      5/29/25 4:05:39 PM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova PLC filed SEC Form 8-K: Regulation FD Disclosure

      8-K - LivaNova PLC (0001639691) (Filer)

      5/21/25 4:08:06 PM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by LivaNova PLC

      SCHEDULE 13G/A - LivaNova PLC (0001639691) (Subject)

      5/13/25 4:00:17 PM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LIVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by LivaNova PLC

      SC 13G - LivaNova PLC (0001639691) (Subject)

      4/17/24 4:19:05 PM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by LivaNova PLC (Amendment)

      SC 13G/A - LivaNova PLC (0001639691) (Subject)

      2/12/24 4:01:13 PM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by LivaNova PLC (Amendment)

      SC 13G/A - LivaNova PLC (0001639691) (Subject)

      1/23/24 11:52:27 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care